Alex S Keuroghlian1, Sari L Reisner2, Jaclyn M White3, Roger D Weiss4. 1. The Fenway Institute, Fenway Health, 1340 Boylston Street, Boston, MA 02215, USA; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. 2. The Fenway Institute, Fenway Health, 1340 Boylston Street, Boston, MA 02215, USA; Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. Electronic address: sreisner@fenwayhealth.org. 3. The Fenway Institute, Fenway Health, 1340 Boylston Street, Boston, MA 02215, USA; Chronic Disease Epidemiology, Yale School of Public Health, 333 Cedar Street, New Haven, CT 06510, USA. 4. Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA.
Abstract
BACKGROUND: Transgender people have elevated substance use prevalence compared with the U.S. general population, however no studies have comprehensively examined the relationship of psychosocial risk factors to substance use and substance use disorder (SUD) treatment among both male-to-female (MTF) and female-to-male (FTM) transgender adults. METHODS: Secondary data analysis of a 2013 community-based survey of transgender adults in Massachusetts (N=452) was conducted. Adjusted multivariable logistic regression models were fit to examine the relationship of four risk factor domains with SUD treatment history and recent substance use: (1) demographics; (2) gender-related characteristics; (3) mental health; (4) socio-structural factors. Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (95% CI) were estimated. RESULTS: Ten percent of the sample reported lifetime SUD treatment. Factors associated with significant increase in odds of lifetime SUD treatment alongside recent substance use (all p<0.05) were: (1) older age (aOR=1.02; 95% CI=1.01-1.04), higher educational attainment (aOR=3.59; 95% CI=2.35-5.50), low income (aOR=0.58; 95% CI=0.39-0.86); (2) MTF identity (aOR=3.03; 95% CI=1.95-4.67), gender-affirming medical care (aOR=1.99; 95% CI=1.32-3.00); (3) intimate partner violence (aOR=1.68; 95% CI=1.13-2.49), posttraumatic stress disorder (aOR=2.56; 95% CI=1.69-3.88), depression (aOR=2.30; 95% CI=1.58-3.35), mental health treatment (aOR=1.65; 95% CI=1.11-2.45); (4) discrimination (aOR=1.90; 95% CI=1.22-2.95), unstable housing (aOR=1.80; 95% CI=1.21-2.67), and sex work (aOR=2.48; 95% CI=1.24-4.95). CONCLUSIONS: Substance use and SUD treatment among transgender adults are associated with demographic, gender-related, mental health, and socio-structural risk factors. Studies are warranted that identify SUD treatment barriers, and integrate SUD treatment with psychosocial and structural interventions for a diverse spectrum of transgender adults.
BACKGROUND: Transgender people have elevated substance use prevalence compared with the U.S. general population, however no studies have comprehensively examined the relationship of psychosocial risk factors to substance use and substance use disorder (SUD) treatment among both male-to-female (MTF) and female-to-male (FTM) transgender adults. METHODS: Secondary data analysis of a 2013 community-based survey of transgender adults in Massachusetts (N=452) was conducted. Adjusted multivariable logistic regression models were fit to examine the relationship of four risk factor domains with SUD treatment history and recent substance use: (1) demographics; (2) gender-related characteristics; (3) mental health; (4) socio-structural factors. Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (95% CI) were estimated. RESULTS: Ten percent of the sample reported lifetime SUD treatment. Factors associated with significant increase in odds of lifetime SUD treatment alongside recent substance use (all p<0.05) were: (1) older age (aOR=1.02; 95% CI=1.01-1.04), higher educational attainment (aOR=3.59; 95% CI=2.35-5.50), low income (aOR=0.58; 95% CI=0.39-0.86); (2) MTF identity (aOR=3.03; 95% CI=1.95-4.67), gender-affirming medical care (aOR=1.99; 95% CI=1.32-3.00); (3) intimate partner violence (aOR=1.68; 95% CI=1.13-2.49), posttraumatic stress disorder (aOR=2.56; 95% CI=1.69-3.88), depression (aOR=2.30; 95% CI=1.58-3.35), mental health treatment (aOR=1.65; 95% CI=1.11-2.45); (4) discrimination (aOR=1.90; 95% CI=1.22-2.95), unstable housing (aOR=1.80; 95% CI=1.21-2.67), and sex work (aOR=2.48; 95% CI=1.24-4.95). CONCLUSIONS: Substance use and SUD treatment among transgender adults are associated with demographic, gender-related, mental health, and socio-structural risk factors. Studies are warranted that identify SUD treatment barriers, and integrate SUD treatment with psychosocial and structural interventions for a diverse spectrum of transgender adults.
Authors: Larry Nuttbrock; Walter Bockting; Andrew Rosenblum; Sel Hwahng; Mona Mason; Monica Macri; Jeffrey Becker Journal: Am J Public Health Date: 2013-12-12 Impact factor: 9.308
Authors: Karen I Fredriksen-Goldsen; Loree Cook-Daniels; Hyun-Jun Kim; Elena A Erosheva; Charles A Emlet; Charles P Hoy-Ellis; Jayn Goldsen; Anna Muraco Journal: Gerontologist Date: 2013-03-27
Authors: Larry Nuttbrock; Walter Bockting; Andrew Rosenblum; Sel Hwahng; Mona Mason; Monica Macri; Jeffrey Becker Journal: Am J Public Health Date: 2014-09-11 Impact factor: 9.308
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Eric G Benotsch; Rick Zimmerman; Laurie Cathers; Shawn McNulty; Juan Pierce; Ted Heck; Paul B Perrin; Daniel Snipes Journal: Drug Alcohol Depend Date: 2013-03-17 Impact factor: 4.492
Authors: Matthew J Mimiaga; Jaclyn M W Hughto; Katie B Biello; Christopher M Santostefano; Lisa M Kuhns; Sari L Reisner; Robert Garofalo Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Ethan C Cicero; Sari L Reisner; Susan G Silva; Elizabeth I Merwin; Janice C Humphreys Journal: ANS Adv Nurs Sci Date: 2019 Apr/Jun Impact factor: 1.824
Authors: Paul A Gilbert; Lauren E Pass; Alex S Keuroghlian; Tom K Greenfield; Sari L Reisner Journal: Drug Alcohol Depend Date: 2018-03-10 Impact factor: 4.492
Authors: Gregory Phillips Ii; Dylan Felt; David J McCuskey; Rachel Marro; Jacob Broschart; Michael E Newcomb; Sarah W Whitton Journal: Addict Behav Date: 2020-03-28 Impact factor: 3.913
Authors: Noor Beckwith; Michal J McDowell; Sari L Reisner; Shayne Zaslow; Roger D Weiss; Kenneth H Mayer; Alex S Keuroghlian Journal: LGBT Health Date: 2019-02-01 Impact factor: 4.151